Want to see IN:GUJTHEM full AI Analyst Report?
Top Page
Gujarat Themis Biosyn Ltd
(GUJTHEM)
Select Model
Select Model
Rating:58Neutral
Price Target:
₹428.00
▼(-0.93% Downside)
Action:Reiterated
Date:08/25/26
The score is held back primarily by weakened cash-flow quality and higher leverage despite strong reported profitability and rapid revenue growth. Technicals are supportive of an uptrend but appear overbought, and the very high P/E with minimal dividend yield further limits the overall attractiveness.
Positive Factors
B2B API manufacturing platform
API and intermediate manufacturing supplies inputs to finished-drug producers through domestic and export sales. This B2B position supports recurring industrial demand and gives the company exposure to pharmaceutical production growth, although customer concentration is not provided.
Negative Factors
Sharp gross-margin compression
The steep gross-margin decline indicates weaker cost absorption, pricing, product mix, or input-cost economics. If persistent, it could limit the benefit of strong sales growth and reduce the company’s ability to convert expanding API volumes into durable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
B2B API manufacturing platform
API and intermediate manufacturing supplies inputs to finished-drug producers through domestic and export sales. This B2B position supports recurring industrial demand and gives the company exposure to pharmaceutical production growth, although customer concentration is not provided.
Read all positive factors
Gujarat Themis Biosyn Ltd (GUJTHEM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹44.87B
Dividend Yield0.16%
Average Volume (3M)13.79K
Price to Earnings (P/E)92.0
Beta (1Y)1.99
Revenue Growth17.51%
EPS Growth9.17%
CountryIN
Employees221
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.41
Shares Outstanding108,965,260
10 Day Avg. Volume24,440
30 Day Avg. Volume13,787
Financial Highlights & Ratios
PEG Ratio-11.90
Price to Book (P/B)8.62
Price to Sales (P/S)14.96
P/FCF Ratio-19.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.9
Revenue Forecast (FY)₹1.88B
Gujarat Themis Biosyn Ltd Business Overview & Revenue Model
Company Description
Gujarat Themis Biosyn Ltd. is an Indian company primarily involved in the creation of pharmaceuticals and medicinal chemicals. The firm also supplies bulk drugs via a job work model within India. Its product offerings include important compounds s...
How the Company Makes Money
Gujarat Themis Biosyn Ltd primarily makes money by manufacturing and selling APIs and pharmaceutical intermediates to other pharmaceutical companies (business-to-business), where revenue is recognized from product sales/contracts for these materia...
Gujarat Themis Biosyn Ltd Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
64
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 800.74M | 1.66B | 1.51B |
| Gross Profit | 642.88M | 769.25M | 1.19B |
| EBITDA | 390.15M | 779.58M | 714.23M |
| Net Income | 262.62M | 466.81M | 487.72M |
Balance Sheet | |||
| Total Assets | 3.77B | 5.03B | 3.01B |
| Cash, Cash Equivalents and Short-Term Investments | 103.83M | 64.18M | 116.94M |
| Total Debt | 714.92M | 1.62B | 304.70M |
| Total Liabilities | 1.12B | 2.16B | 529.31M |
| Stockholders Equity | 2.64B | 2.88B | 2.48B |
Cash Flow | |||
| Free Cash Flow | -600.86M | -1.28B | -251.22M |
| Operating Cash Flow | 710.39M | 447.42M | 910.29M |
| Investing Cash Flow | -1.30B | -1.73B | -1.12B |
| Financing Cash Flow | 567.21M | 1.21B | 260.14M |
Gujarat Themis Biosyn Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ₹58.72B | 34.96 | ― | 0.50% | 18.56% | 60.06% | |
61 Neutral | ₹48.42B | 558.27 | ― | 16.67% | 10.83% | -89.82% | |
58 Neutral | ₹44.87B | 92.02 | ― | 0.16% | 17.51% | 9.17% | |
57 Neutral | ₹38.79B | 12.71 | ― | 1.34% | 9.43% | 132.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹62.30B | 44.43 | ― | 0.18% | 9.48% | 50.08% | |
50 Neutral | ₹44.67B | 60.78 | ― | 0.02% | 16.70% | 18.73% |
* General Sector Average
IN:GUJTHEM
Gujarat Themis Biosyn Ltd
411.75
28.15
7.34%
IN:GUFICBIO
Gufic Biosciences Limited
445.40
89.08
25.00%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
200.05
89.57
81.07%
IN:MOREPENLAB
Morepen Laboratories Limited
113.70
64.60
131.57%
IN:ORCHPHARMA
Orchid Pharma Limited
954.70
245.55
34.63%
IN:UNICHEMLAB
Unichem Laboratories Limited
550.90
46.80
9.28%
Gujarat Themis Biosyn Ltd Corporate Events
Gujarat Themis Biosyn Files Audited FY26 Results With Clean Audit Opinion
Aug 25, 2026
Gujarat Themis Biosyn Ltd has released its audited financial statements for the quarter and full year ended March 31, 2026, following board approval in May. The disclosure has been made to both BSE and NSE in line with SEBI’s listing require...
Gujarat Themis Biosyn Amends Articles to Loosen Share Issuance Valuation Rules
Aug 23, 2026
Gujarat Themis Biosyn Ltd has secured shareholder approval via a special resolution at an Extraordinary General Meeting on 22 August 2026 to amend its Articles of Association. The amendment, disclosed under SEBI Listing Obligations and Disclosure ...
Gujarat Themis Biosyn Shareholders Approve Key Amendment to Articles of Association
Aug 23, 2026
Gujarat Themis Biosyn Ltd has amended its Articles of Association following shareholder approval via a special resolution passed through a postal ballot on 22 August 2026. The change targets Article 13(1), Clause (c), which governs the companyR...
Gujarat Themis Biosyn Secures Shareholder Nod for QIP Fundraising Plan
Aug 22, 2026
Gujarat Themis Biosyn Ltd has reported the results of a postal ballot conducted via remote e-voting to approve a special resolution for raising funds through an issue of equity shares via Qualified Institutions Placement. The promoter group did no...
Gujarat Themis Biosyn Publishes Q1 FY27 Earnings Call Transcript
Aug 14, 2026
Gujarat Themis Biosyn Limited has released the transcript of its Q1 FY27 earnings conference call with analysts and investors, held on August 10, 2026. The call, led by Managing Director Dr. Sachin Patel and Chief Financial Officer Krupesh Patel, ...
Gujarat Themis Biosyn Publishes Q1 FY27 Unaudited Results in Line with SEBI Norms
Aug 8, 2026
Gujarat Themis Biosyn Ltd is an India-based pharmaceutical and biosciences company, operating a manufacturing facility in Vapi, Gujarat and maintaining a corporate office in Mumbai. It is listed on BSE and NSE, reflecting a long-standing presence ...
Gujarat Themis Biosyn Sets August EGM, Activates Remote E-Voting
Aug 1, 2026
Gujarat Themis Biosyn Ltd has notified the stock exchanges that it has published a newspaper advertisement regarding an upcoming Extra-Ordinary General Meeting. The company has circulated the EGM notice electronically to shareholders with register...
Gujarat Themis Biosyn Launches Fully Electronic Postal Ballot for Shareholder Approval
Jul 23, 2026
Gujarat Themis Biosyn Ltd has initiated a postal ballot process, conducted entirely through remote e-voting, to seek shareholder approval for a resolution in line with provisions of the Companies Act, SEBI Listing Regulations, and recent Ministry ...
Gujarat Themis Biosyn Seeks Shareholder Nod via Fully Electronic Postal Ballot
Jun 8, 2026
Gujarat Themis Biosyn Ltd has launched a postal ballot process, conducted exclusively via remote e-voting, to seek shareholder approval for a resolution in line with provisions of the Companies Act and SEBI listing regulations. The company has eng...
Gujarat Themis Biosyn Clears Rs 1,000 Crore QIP, Preferential Issue for Growth Funding
Jun 6, 2026
Gujarat Themis Biosyn Ltd’s board has approved plans to raise up to Rs 1,000 crore through a Qualified Institutions Placement, allowing the company to issue equity shares and other convertible securities in one or more tranches, subject to s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.